Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $43.20.

A number of research firms have recently weighed in on LYEL. B. Riley Financial began coverage on Lyell Immunopharma in a research note on Wednesday. They set a “buy” rating and a $44.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Zacks Research upgraded shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Needham & Company LLC reissued a “buy” rating and issued a $44.00 price target on shares of Lyell Immunopharma in a report on Monday, June 15th. Finally, Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th.

Lyell Immunopharma Trading Down 1.2%

Shares of NASDAQ:LYEL opened at $12.63 on Friday. The stock has a market capitalization of $309.44 million, a P/E ratio of -0.92 and a beta of -0.06. The stock’s 50-day moving average price is $14.14 and its 200-day moving average price is $19.78. Lyell Immunopharma has a 12-month low of $9.28 and a 12-month high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. As a group, research analysts predict that Lyell Immunopharma will post -7.69 EPS for the current year.

Institutional Trading of Lyell Immunopharma

Several large investors have recently modified their holdings of LYEL. MWG Caph Ltd bought a new position in Lyell Immunopharma during the 4th quarter valued at approximately $31,030,000. BBR Partners LLC purchased a new stake in Lyell Immunopharma in the 4th quarter worth approximately $210,000. Jane Street Group LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter worth approximately $382,000. Two Sigma Investments LP grew its position in shares of Lyell Immunopharma by 107.0% in the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock worth $338,000 after buying an additional 10,768 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Lyell Immunopharma during the second quarter valued at approximately $159,000. 66.05% of the stock is owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.